I guess I have to teach you Causation vs. Correlation in biotechs, how fear drives some decisions and how difficult is it to get patient and relatives consent on trials, having said about trial when is RAC starting its trials This is a single-patient case report, which is insufficient to draw meaningful conclusions about CHECKvacc's clinical utility. The results may not be generalizable to a larger population, its always look at sample size and anecdotal nature of trials, why most of retails fail in biotech investments is because they do not understand the nitty gritty and complex nature of the trials, questions which will be answered in subsequent trials and results 1. What was the rationale for choosing CHECKvacc for this patient initially?2. Was the response time (25 days later) consistent with CHECKvacc’s expected mechanism of action? Wait and watch this space, share price shows promise and all RAC grave diggers are back in full force...
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
This is a single-patient case report, which is insufficient to draw meaningful conclusions about CHECKvacc's clinical utility. The results may not be generalizable to a larger population, its always look at sample size and anecdotal nature of trials, why most of retails fail in biotech investments is because they do not understand the nitty gritty and complex nature of the trials, questions which will be answered in subsequent trials and results
(20min delay)